Welcome to our dedicated page for Horizon Therapeutics Pub L news (Ticker: HZNP), a resource for investors and traders seeking the latest updates and insights on Horizon Therapeutics Pub L stock.
Horizon Therapeutics plc (NASDAQ: HZNP) is a global biotechnology leader focused on developing therapies for rare, autoimmune, and severe inflammatory diseases. This dedicated news hub provides investors and healthcare professionals with timely updates on regulatory milestones, research breakthroughs, and strategic corporate initiatives shaping the company's trajectory.
Access authoritative information on Horizon's innovative treatments like TEPEZZA® and KRYSTEXXA®, along with analysis of key developments including partnership announcements and regulatory filings. Our curated news collection serves as your primary resource for understanding Horizon's position in the biopharmaceutical landscape and its commitment to addressing unmet medical needs.
Key updates cover clinical trial progress, FDA communications, financial results, and major corporate events such as Horizon's pending acquisition by Amgen following FTC clearance. All content is sourced from official releases and verified channels to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to Horizon Therapeutics' evolving story. For additional context on the company's mission and pipeline, visit their official website at HorizonTherapeutics.com.
Horizon Therapeutics and the Cubs have partnered for a Legacy Partnership, launching a Cubs STEAM Program aimed at engaging middle and high school students in science through baseball. The program will feature a citywide science camp and fair, facilitating hands-on learning about the intersection of science and baseball. Additionally, the partnership includes an event during Spring Training 2022 to raise awareness about rare diseases. Horizon's initiative seeks to nurture future science leaders while highlighting the challenges faced by those with rare diseases.
Horizon Therapeutics plc (Nasdaq: HZNP) has enrolled the first patient in the FORWARD trial, assessing a new monthly dosing of 16 mg KRYSTEXXA with methotrexate for treating uncontrolled gout. This trial aims to lower treatment frequency, potentially enhancing patient experience. The primary endpoint measures responder rates in maintaining low serum uric acid levels. With 30 participants targeted, the protocol remains unapproved by health authorities. Safety concerns exist regarding anaphylaxis and infusion reactions during treatment.
Horizon Therapeutics plc (Nasdaq: HZNP) announced that Mitsubishi Tanabe Pharma Corporation received approval for UPLIZNA from the Japanese Ministry of Health. This drug is aimed at preventing relapses in neuromyelitis optica spectrum disorder (NMOSD). MHPC holds rights for UPLIZNA's development in several Asian markets. Horizon stands to gain milestone payments and sales-related revenues. Tim Walbert emphasized the approval's significance for NMOSD patients and Horizon's commitment to expanding treatment options globally.
Horizon Therapeutics plc (Nasdaq: HZNP) has launched The Horizon Prize, an annual global innovation challenge in partnership with MIT Solve, aimed at enhancing diagnosis and care for individuals with rare diseases. Each year, the challenge will focus on a unique question to stimulate innovative solutions. This year’s inquiry targets utilizing technology to expedite accurate care for rare disease patients. With an annual funding pool of up to $150,000 for two teams, the initiative seeks solutions leveraging big data, patient advocacy, and collaboration among stakeholders in the healthcare ecosystem.
Horizon Therapeutics (Nasdaq: HZNP) has acquired Viela Bio (Nasdaq: VIE) for $53.00 per share, a transaction valued at over $3 billion. This acquisition enhances Horizon's commercial portfolio in rare diseases, particularly with UPLIZNA, the first FDA-approved treatment for neuromyelitis optica spectrum disorder. The deal will strengthen Horizon's R&D capabilities and add a mid-stage biologics pipeline targeting autoimmune diseases. However, Horizon expects a $140 million decrease in adjusted EBITDA for 2021 due to increased R&D expenditures.
Horizon Therapeutics plc (Nasdaq: HZNP) will participate in the Cowen and Company 41st Annual Health Care Conference (Virtual) on March 2, 2021, at 1:30 p.m. ET. The event will be webcast live, and the link can be found on Horizon's website. A replay of the presentation will be available afterward. Horizon focuses on developing therapeutics for patients with rare and rheumatic diseases, aiming to transform lives through science and compassion.
Horizon Therapeutics plc (Nasdaq: HZNP) reported record financial results for Q4 and the full year 2020, highlighting a 105% increase in Q4 net sales to $745.3 million and 69% growth in FY 2020 to $2.2 billion. The company announced positive guidance for 2021, projecting net sales between $2.70 billion to $2.80 billion. CEO Tim Walbert emphasized the successful launch of TEPEZZA and a definitive agreement to acquire Viela Bio, adding to its robust pipeline. However, net income saw a significant decline of 68% in Q4.
